Q3 2018 EPS Estimates for Catalent Inc (CTLT) Lowered by Analyst
Catalent Inc (NYSE:CTLT) – Equities researchers at William Blair dropped their Q3 2018 EPS estimates for Catalent in a note issued to investors on Tuesday. William Blair analyst J. Kreger now forecasts that the company will post earnings per share of $0.36 for the quarter, down from their previous estimate of $0.42. William Blair also issued estimates for Catalent’s Q4 2018 earnings at $0.55 EPS, Q2 2019 earnings at $0.44 EPS, Q3 2019 earnings at $0.42 EPS, Q4 2019 earnings at $0.66 EPS and FY2019 earnings at $1.77 EPS.
Catalent (NYSE:CTLT) last posted its earnings results on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.10. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The firm had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. During the same quarter last year, the firm earned $0.27 EPS. The firm’s revenue for the quarter was up 25.3% on a year-over-year basis.
Shares of Catalent (NYSE:CTLT) opened at $40.47 on Friday. Catalent has a 1-year low of $27.48 and a 1-year high of $47.87. The company has a debt-to-equity ratio of 2.66, a current ratio of 2.22 and a quick ratio of 2.49. The firm has a market cap of $5,410.07, a P/E ratio of 71.00, a P/E/G ratio of 2.33 and a beta of 1.47.
In other news, Director Uwe Roehrhoff acquired 7,500 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The stock was acquired at an average cost of $39.22 per share, with a total value of $294,150.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. State Street Corp lifted its position in shares of Catalent by 10.7% during the 2nd quarter. State Street Corp now owns 4,315,841 shares of the company’s stock worth $151,488,000 after purchasing an additional 418,196 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Catalent by 755.3% during the 4th quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock worth $108,108,000 after purchasing an additional 2,323,971 shares during the last quarter. Earnest Partners LLC lifted its position in shares of Catalent by 0.5% during the 3rd quarter. Earnest Partners LLC now owns 2,570,156 shares of the company’s stock worth $102,601,000 after purchasing an additional 12,652 shares during the last quarter. Macquarie Group Ltd. lifted its position in shares of Catalent by 15.8% during the 3rd quarter. Macquarie Group Ltd. now owns 2,069,323 shares of the company’s stock worth $82,607,000 after purchasing an additional 282,559 shares during the last quarter. Finally, Brown Advisory Inc. lifted its position in shares of Catalent by 7.1% during the 3rd quarter. Brown Advisory Inc. now owns 1,948,514 shares of the company’s stock worth $77,784,000 after purchasing an additional 129,966 shares during the last quarter. 98.86% of the stock is owned by institutional investors and hedge funds.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.